CSL Limited (ASX: CSL)
Analysts at UBS have retained their buy rating and lifted the price target on this biotherapeutics company’s shares to $346.00. This follows an FY 2020 result which was in line with expectations and positive guidance for the year ahead. Overall, it appears to see a decent risk/reward on offer with its shares at the current level. I would have to agree with UBS on this one and believe CSL is a great option for investors.
- Forums
- ASX - By Stock
- CSL
- UBS lifted the price target for CSL
UBS lifted the price target for CSL
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CSL (ASX) to my watchlist
|
|||||
Last
$292.08 |
Change
-0.520(0.18%) |
Mkt cap ! $141.1B |
Open | High | Low | Value | Volume |
$290.71 | $293.00 | $290.55 | $125.8M | 431.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $292.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$292.10 | 712 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 76 | 291.670 |
1 | 15 | 291.600 |
2 | 373 | 291.410 |
1 | 445 | 291.250 |
1 | 6 | 291.000 |
Price($) | Vol. | No. |
---|---|---|
292.100 | 712 | 3 |
292.110 | 967 | 1 |
292.180 | 697 | 1 |
292.230 | 1245 | 1 |
292.290 | 962 | 1 |
Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
Featured News
CSL (ASX) Chart |